solanezumab Articles
Lilly plans new trial of Alzheimer's hope solanezumab
13 December 2012
Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development
4 December 2012
Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial
11 October 2012
Alzheimer's drug market to more than triple to $13.3 billion in 2019 in top seven markets, fuelled by new biologic agents
10 September 2010
Double dose of woes for Eli Lilly, as it drops Ph III AD drug semagacestat and FDA panel could say no to expanding use of Cymbalta
18 August 2010
Showing 1-9 of 9 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
